Exchange: NASDAQ·Updated 07:41 PM EDT
CRIS logo

CRISCuris Inc

$4.82
$0.08
(1.72%)
Today
Closed $4.73
$0.09
(1.90%)
After Hours
EarningsAug 11
Mkt Cap$9.06M
Vol46,906.00
News
all
press releases
Why Q32 Bio Shares Are Trading Higher By Around 30%; Here Are 20 Stocks Moving Premarket
Gainers: Q32 Bio up 29.6%, Mint up 75.8%, Fast Track up 58.2%, eLong up 33.4%, Sobr Safe up 29.2%, Eshallgo up 20.3%, Curis up 10.9%, Sky Quarry up 10.6%, Accuray up 9.5%, Bitzero up 5.5%. Losers: Global Mofy down 25.3%, Jiuzi down 22.1%, Julong down 21.4%, Haoxi down 20.4%, Sadot down 20.4%.read...
Benzinga
News Placeholder
More News
News Placeholder
Curis Consents First Six Patients in TakeAim CLL Study
Curis Consents First Six Patients in TakeAim CLL Study Curis Consents First Six Patients in TakeAim CLL Study PR Newswire LEXINGTON, Mass., July 6, 2026 LEXINGTON, Mass., July 6, 2026 /PRNewswire/ -- Curis, Inc. (NASDAQ: CRIS), a biotechnology company focused on the development of emavusertib...
PR Newswire
News Placeholder
Why Did Curis (CRIS) Stock Soar After Hours?
Curis, Inc. shares surged 8.51% after the bell after the company confirmed its approved reverse stock split will take effect on Thursday.read more...
Benzinga
News Placeholder
12 Health Care Stocks Moving In Wednesday's After-Market Session
Gainers Curis (NASDAQ:CRIS) stock rose 9.0% to $0.46 during Wednesday's after-market session. The company's market cap stands at $20.3 million. Humacyte (NASDAQ:HUMA) shares moved upwards by 5.45% to $0.71.read more...
Benzinga
News Placeholder
Curis Announces Eleven Active Clinical Sites in TakeAim CLL Study, Reaffirms Patient Dosing Guidance, and Reports Stockholder Approval of Reverse Stock Split
Curis Announces Eleven Active Clinical Sites in TakeAim CLL Study, Reaffirms Patient Dosing Guidance, and Reports Stockholder Approval of Reverse Stock Split Curis Announces Eleven Active Clinical Sites in TakeAim CLL Study, Reaffirms Patient Dosing Guidance, and Reports Stockholder Approval of...
PR Newswire
News Placeholder
Curis Reports Q1 2026 Results: Full Earnings Call Transcript
read more...
Benzinga
News Placeholder
Curis Provides First Quarter 2026 Business Update
Curis Provides First Quarter 2026 Business Update Curis Provides First Quarter 2026 Business Update PR Newswire LEXINGTON, Mass., May 12, 2026 Management to host conference call today at 4:30 p.m...
PR Newswire
News Placeholder
Vericel Corporation (VCEL) Reports Q1 Loss, Beats Revenue Estimates
Vericel (VCEL) delivered earnings and revenue surprises of +17.24% and +7.25%, respectively, for the quarter ended March 2026. Do the numbers hold clues to what lies ahead for the stock?
Zacks
News Placeholder
Curis to Report First Quarter 2026 Financial and Operating Results and Host Conference Call and Webcast on May 12, 2026
Curis to Report First Quarter 2026 Financial and Operating Results and Host Conference Call and Webcast on May 12, 2026 Curis to Report First Quarter 2026 Financial and Operating Results and Host Conference Call and Webcast on May 12, 2026 PR Newswire LEXINGTON, Mass., May 5, 2026 LEXINGTON, Mass...
PR Newswire
News Placeholder
Kiniksa Pharmaceuticals International, plc (KNSA) Tops Q1 Earnings and Revenue Estimates
Kiniksa Pharmaceuticals International, plc (KNSA) delivered earnings and revenue surprises of +50.00% and +5.24%, respectively, for the quarter ended March 2026. Do the numbers hold clues to what lies ahead for the stock?
Zacks
<
1
2
...
>